TY - JOUR
T1 - Rhabdomyosarcoma
AU - Yechieli, Raphael L.
AU - Mandeville, Henry C.
AU - Hiniker, Susan M.
AU - Bernier-Chastagner, Valerie
AU - McGovern, Susan
AU - Scarzello, Giovanni
AU - Wolden, Suzanne
AU - Cameron, Alison
AU - Breneman, John
AU - Fajardo, Raquel Davila
AU - Donaldson, Sarah S.
N1 - Publisher Copyright:
© 2021 Wiley Periodicals LLC
PY - 2021/5
Y1 - 2021/5
N2 - Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.
AB - Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.
KW - Rhabdomyosarcoma
KW - chemotherapy
KW - surgery radiation oncology
UR - http://www.scopus.com/inward/record.url?scp=85103667846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103667846&partnerID=8YFLogxK
U2 - 10.1002/pbc.28254
DO - 10.1002/pbc.28254
M3 - Article
C2 - 33818882
AN - SCOPUS:85103667846
SN - 1545-5009
VL - 68
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - S2
M1 - e28254
ER -